KEYNOTE-667: Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy.

Authors

Christine Mauz-Korholz

Justus-Liebig University of Giessen, Giessen, Germany

Christine Mauz-Korholz , Kara M. Kelly , Frank G. Keller , Lisa Giulino-Roth , Akash Nahar , Arun Balakumaran

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Sign-In

Similar Posters

insert_chart_outlined

Poster

2019 ASCO Annual Meeting

bookmark_border

Phase 2, open-label study of pembrolizumab in children and young adults with newly diagnosed classical hodgkin lymphoma (cHL) with slow early response (SER) to frontline chemotherapy: KEYNOTE-667.

First Author: Christine Mauz-Körholz

insert_chart_outlined

Poster

2023 ASCO Annual Meeting

bookmark_border

Efficacy and safety of pembrolizumab (pembro) in children and young adults with newly diagnosed classical Hodgkin lymphoma (cHL) with slow early response (SER) to front-line chemotherapy (chemo) in the phase 2, open-label, KEYNOTE-667 study.

First Author: Luciana Vinti

insert_chart_outlined

Poster

2022 ASCO Annual Meeting

bookmark_border

Sequential pembrolizumab (pembro) and chemotherapy (chemo) in newly diagnosed, early unfavorable, or advanced-stage classical Hodgkin lymphoma (cHL): The phase 2 KEYNOTE-C11 study.

First Author: Jane N. Winter

insert_chart_outlined

Poster

2017 ASCO Annual Meeting

bookmark_border

Risk-adapted therapy utilizing upfront brentuximab vedotin (Bv) and rituximab (R) with reduced toxicity chemotherapy in children, adolescents, and young adults with Hodgkin lymphoma.

First Author: Jessica Hochberg